Skip to content

Revealing Increased Axonal Loss in Treated HIV Patients

Revealing Increased Axonal Loss in Treated HIV Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02003989
Acronym
OCTIHIV
Enrollment
156
Registered
2013-12-06
Start date
2013-05-31
Completion date
Unknown
Last updated
2016-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Seropositivity

Brief summary

HIV patients may suffer sooner from aging than average population, including brain aging. Our hypothesis is that if brain dysfunctions are explained by a quicker loss of neurons in HIV patients, this loss could be detected earlier by a thinning down of retinal nerve fiber layer (RNFL), compared to non HIV patients of the same age.

Detailed description

The investigators aim to compare the thickness of the RNFL and the thickness of the RCGs measured by spectral domain OCT between patients infected by HIV and patients of same age non infected by HIV.

Interventions

OTHERophthalmologic examination and MRI

thorough investigation of patients, not included in usual care.

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV infection known since at least 10 years * viral load undetectable under ARV treatment since at least 5 years, whatever the type of ARV * lymphocytes CD4 \> 350, whatever the CD4 nadir * signed informed consent

Exclusion criteria

* History of ocular pathology, eye surgery, or intraocular injection * Familial History of glaucoma * ametropia (\>3 dioptres on the sphere and \>1,5 dioptres on the cylinder) * known neurological pathology, active or former * History of ethambutol or synthetic antimalarial drug consumption * History of chemotherapy * Active and regular use of drugs * non-weaned chronic alcoholism * contra indication to MRI * diabetes * cognitive disorders (MoCA\<26) * non covered by health insurance * patient under legal protection * pregnant or breast-feeding woman * Non inclusion criteria for control patients: known HIV infection

Design outcomes

Primary

MeasureTime frame
thickness of the RNFL and the RCGs measured by spectral domain OCT, between the two groups of patientsone day of examinations

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026